Author: David Thomas, CFA
BIO Answers FAQs on Human Genome Editing
Genome editing has been a hot topic in drug discovery research recently, as CRISPR-based preclinical …
Benefiting from Innovative Clinical Trial Designs
Clinical trial success rates have been known to be low for some time now, but …
Does Big Company M&A Impact Small Company M&A?
Over the last few years, we have seen significant consolidation among the large drug manufacturers, …
Improving Oncology Clinical Trials
The 18th Annual BIO CEO & Investor Conference kicked off with a panel focused on oncology …
2015 FDA Approvals: Highest Levels in Over a Decade
2015 was a blockbuster year for FDA approvals of novel new medicines, many of them …
Haves and Have Nots in Biotech Venture Capital
Recent data from the BIO Industry Analysis team tells a story of “haves and have-nots” …
State of the Industry for Emerging Therapeutic Companies
Emerging therapeutic companies are at their strongest point in a decade. In our new report …
Ten Years of Therapeutic Venture Capital
What therapeutic areas have received the most funding in private drug companies over the last …
Therapeutic Licensing and M&A Deals
Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least …
Debunking the Biotech Bubble Talk
The Nasdaq Biotechnology Index (NBI) has been on a wild ride in 2014 with a …